BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7536369)

  • 1. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.
    Akakura K; Akimoto S; Ohki T; Shimazaki J
    Urology; 1995 Apr; 45(4):700-4; discussion 704-5. PubMed ID: 7536369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
    Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
    Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
    Akakura K; Akimoto S; Furuya Y; Ito H
    Eur Urol; 1998; 33(6):567-71. PubMed ID: 9743699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
    Sekido N; Kawai K; Akaza H; Koiso K
    Jpn J Clin Oncol; 1995 Aug; 25(4):164-7. PubMed ID: 7545251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
    Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
    Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports.
    Noguchi K; Teranishi J; Uemura H; Fujikawa N; Saito K; Murai T
    Int J Urol; 2006 Sep; 13(9):1259-61. PubMed ID: 16984567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
    Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
    Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.
    Dawson NA; McLeod DG
    J Urol; 1995 Jun; 153(6):1946-7. PubMed ID: 7538601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiandrogen withdrawal syndrome].
    Akimoto S
    Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
    Akaza H; Usami M; Kotake T; Koiso K; Aso Y
    Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
    Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
    Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
    Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
    Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
    Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
    Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
    Ryan CJ; Halabi S; Ou SS; Vogelzang NJ; Kantoff P; Small EJ
    Clin Cancer Res; 2007 Apr; 13(7):2030-7. PubMed ID: 17404083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
    El-Gabry EA; Strup SE; Gomella LG
    Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy.
    Okihara K; Ukimura O; Kanemitsu N; Mizutani Y; Kawauchi A; Miki T;
    Int J Urol; 2007 Feb; 14(2):128-32. PubMed ID: 17302569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.